{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:18:18Z","timestamp":1793596698121,"version":"4.5.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-cbr240012-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>There is limited evidence with regard to the benefit of adjuvant chemotherapy chemoradiotherapy in resected gallbladder cancers (GBCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To establish a baseline survival rate for operated GBCs in patients receiving either gemcitabine plus cisplatin (GC) or capecitabine and capecitabine concurrent with chemoradiation (CCRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The GECCOR-GB study was a multicenter, open-label, randomized phase 2 noncomparator \u201cpick the winner\u201d design trial of adjuvant GC and CCRT in patients with resected histologically confirmed adenocarcinoma or adenosquamous carcinoma of the gallbladder, (stage II\/III) with no local residual tumor (R0) or microscopic residual tumor (R1). The study was carried out in 3 tertiary cancer institutions in India. Patients 18 years or older with adequate end-organ functions, and Eastern Cooperative Oncology Group Performance Status of 1 or lower between May 2019 and February 2022 were enrolled. The cutoff date for data analysis was February 28, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-7\">\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients were randomized 1:1 to receive either GC every 3 weeks (maximum of 6 cycles) or CCRT comprising capecitabine with concurrent chemoradiation (capecitabine concurrent with radiotherapy) sandwiched between capecitabine chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was disease-free survival (DFS) at 1 year in randomized patients. This study was conducted as 2 parallel, single-stage phase 2 clinical trials. Within each treatment arm, a 1-year DFS rate of less than 59% was considered as insufficient activity, whereas a 1-year DFS rate of 77% or higher would be considered as sufficient activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a median follow-up of 23 months, 90 patients were randomized, 45 in each arm. Overall, there were 31 women (69%) and 14 men (31%) in the GC arm with a mean (range) age of 56 (33-72) years and 34 women (76%) and 11 men (24%) in the CCRT group with a mean (range) age of 55 (26-69) years. In the GC and CCRT arms, 1-year DFS and estimated 2-year DFS was 88.9% (95% CI, 79.5-98.3) and 74.8% (95% CI, 60.4-89.2), and 77.8% (95% CI, 65.4-90.2) and 74.8% (95% CI, 59.9-86.3), respectively. Completion rates for planned treatment was 82% in the GC arm and 62% in the CCRT arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this randomized clinical trial, GC and CCRT crossed the prespecified trial end points of 1-year DFS in patients with resected stage II\/III GBCs. The results set a baseline for a larger phase 3 trial evaluating both regimens in operated GBCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240012-11\">\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: CTRI\/2019\/05\/019323I<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1944","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:07:36Z","timestamp":1720004856000},"page":"1116","source":"Crossref","is-referenced-by-count":23,"title":["Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Vikas","family":"Ostwal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Patkar","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Engineer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Parulekar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Mandavkar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Krishnatry","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivakumar","family":"Gudi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgatosh","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Homi Bhabha Cancer Hospital (HBCH), Civil Hospital Campus, Sangrur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapas Kumar","family":"Dora","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Homi Bhabha Cancer Hospital (HBCH), Civil Hospital Campus, Sangrur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Homi Bhabha Cancer Hospital (HBCH), Civil Hospital Campus, Sangrur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Chaugule","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Naughane","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuprita","family":"Daddi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshree","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman Kumar","family":"Ankathi","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, TMH, Mumbai, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"cbr240012r1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"5","key":"cbr240012r2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"cbr240012r3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","article-title":"Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study.","volume":"18","author":"Siebenh\u00fcner","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"cbr240012r4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12032-018-1115-6","article-title":"Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.","volume":"35","author":"Ostwal","year":"2018","journal-title":"Med Oncol"},{"issue":"24","key":"cbr240012r5","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma.","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"cbr240012r6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study.","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"cbr240012r7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10372","key":"cbr240012r8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"cbr240012r9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3857\/roj.2017.00388","article-title":"Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy.","volume":"35","author":"Kim","year":"2017","journal-title":"Radiat Oncol J"},{"issue":"8","key":"cbr240012r10","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.v98:8","article-title":"Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.","volume":"98","author":"Jarnagin","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"cbr240012r11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.hpb.2016.05.016","article-title":"Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium.","volume":"18","author":"Margonis","year":"2016","journal-title":"HPB (Oxford)"},{"issue":"8","key":"cbr240012r12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study.","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"cbr240012r13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11605-021-05143-6","article-title":"Prospective randomized controlled trial comparing adjuvant chemotherapy vs. no chemotherapy for patients with carcinoma of gallbladder undergoing curative resection.","volume":"26","author":"Saluja","year":"2022","journal-title":"J Gastrointest Surg"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2820694\/jamaoncology_ostwal_2024_br_240012_1723659901.17869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:02:06Z","timestamp":1723719726000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2820694"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1944","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}